A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy

Eur J Cancer. 2021 Apr:147:161-163. doi: 10.1016/j.ejca.2021.02.001. Epub 2021 Mar 5.

Authors

Alizé Pacaud¹, Samuel Amintas², Lise Boussemart³, David Cappellen², Emilie Gérard⁴

Affiliations

¹ Department of Dermatology, Hôpital Saint André, University Hospital Bordeaux, Bordeaux, France.
² Department of Molecular Biology, Hôpital Haut Levêque, University Hospital Bordeaux, Bordeaux, France.
³ Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France.
⁴ Department of Dermatology, Hôpital Saint André, University Hospital Bordeaux, Bordeaux, France. Electronic address: [email protected].

PMID: 33684875
DOI: 10.1016/j.ejca.2021.02.001

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Azetidines / therapeutic use*
Biomarkers, Tumor / genetics*
Female
Gene Fusion*
Humans
Immune Checkpoint Inhibitors / therapeutic use
Melanoma / drug therapy*
Melanoma / enzymology
Melanoma / genetics
Melanoma / secondary
Middle Aged
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
Mitogen-Activated Protein Kinase Kinases / metabolism
Mutation
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins c-raf / genetics*
Pyridones / therapeutic use*
Pyrimidinones / therapeutic use*
Skin Neoplasms / drug therapy*
Skin Neoplasms / enzymology
Skin Neoplasms / genetics
Skin Neoplasms / pathology
Treatment Outcome

Substances

Azetidines
Biomarkers, Tumor
Immune Checkpoint Inhibitors
Piperidines
Protein Kinase Inhibitors
Pyridones
Pyrimidinones
trametinib
Proto-Oncogene Proteins c-raf
Raf1 protein, human
Mitogen-Activated Protein Kinase Kinases
cobimetinib